Intervention* | Probability of response, median (95% credible interval) | ||||||||
All patients | bDMARD-naïve | bDMARD-exposed | |||||||
ACR 20 | ACR 50 | ACR 70 | ACR 20 | ACR 50 | ACR 70 | ACR 20 | ACR 50 | ACR 70 | |
Brodalumab 210 mg | 48.6% (37.6, 59.7) | 24.6% (16.7, 34.3) | 9.8% (16.7, 34.3) | 53.1% (40.4, 65.3) | 28.5% (18.7, 40) | 13% (18.7, 40) | 32.3% (15.9, 53.1) | 14.7% (5.6, 30.6) | 5.4% (5.6, 30.6) |
Ixekizumab 80 mg every two weeks | 56% (44.5, 66.6) | 30.9% (21.5, 41.3) | 13.4% (21.5, 41.3) | 60.2% (45.1, 74.2) | 34.9% (22.1, 50.1) | 17.3% (22.1, 50.1) | 47.2% (28.1, 67) | 25.5% (12.1, 44.1) | 11.2% (12.1, 44.1) |
Ixekizumab 80 mg every four weeks | 55.1% (44.5, 64.8) | 30% (21.5, 39.3) | 12.9% (21.5, 39.3) | 55.5% (43.1, 67.7) | 30.6% (20.6, 42.5) | 14.4% (20.6, 42.5) | 49.4% (29.9, 69) | 27.3% (13.2, 46.4) | 12.2% (13.2, 46.4) |
Secukinumab 150 mg | 51.5% (42.7, 60.4) | 27% (20.2, 35) | 11.1% (20.2, 35) | 54.2% (45.4, 63.3) † | 29.4% (22.2, 38) † | 13.6% (22.2, 38) † | 40.7% (23.7, 59.7) † | 20.5% (9.6, 36.6) † | 8.3% (9.6, 36.6) † |
Secukinumab 300 mg | 56.3% (47.4, 64.8) | 31.2% (23.7, 39.4) | 13.6% (23.7, 39.4) | 57.2% (48.2, 66.3)† | 32.1% (24.4, 41.1)† | 15.4% (24.4, 41.1)† | 51% (32.2, 69.4) † | 28.6% (14.7, 46.9)† | 13.1% (14.7, 46.9)† |
Guselkumab 100 mg every eight weeks | 51.6% (40.5, 61) | 27.1% (18.6, 35.5) | 11.1% (18.6, 35.5) | 52.6% (41, 63.4)† | 28.1% (19.1, 38.1)† | 12.8% (19.1, 38.1)† | 63% (36.2, 84.8)‡ | 39.8% (17.3, 67)‡ | 20.7% (17.3, 67)‡ |
Tildrakizumab 100 mg every twelve weeks | 48.9% (32.9, 64.3) | 24.9% (13.7, 38.8) | 9.9% (13.7, 38.8) | – | – | – | – | – | – |
Ustekinumab 45 mg | 34.2% (24.6, 45.9) | 14.5% (9.1, 22.5) | 4.8% (9.1, 22.5) | 41.8% (29.7, 55.1) | 19.6% (11.9, 30.2) | 7.9% (11.9, 30.2) | 32.9% (13.6, 59) | 15.1% (4.6, 36) | 5.6% (4.6, 36) |
Ustekinumab 90 mg | 41.6% (32, 52.7) | 19.4% (13.2, 28) | 7.1% (13.2, 28) | 46% (33.5, 59) | 22.8% (14.1, 33.8) | 9.6% (14.1, 33.8) | 31.9% (13, 57.9) | 14.5% (4.3, 34.9) | 5.3% (4.3, 34.9) |
Adalimumab 40 mg every two weeks | 55.8% (46.5, 63.6) | 30.7% (23, 38.1) | 13.3% (23, 38.1) | 55.5% (46.3, 64.8) | 30.6% (22.9, 39.4) | 14.4% (22.9, 39.4) | – | – | – |
Certolizumab 200 mg every two weeks | 61.3% (47.1, 73.8) | 35.8% (23.5, 49.4) | 16.6% (23.5, 49.4) | 55.8% (41, 70.3) | 30.9% (19.1, 45.4) | 14.6% (19.1, 45.4) | 65.3% (36.4, 88.1) | 42.2% (17.5, 72.3) | 22.5% (17.5, 72.3) |
Certolizumab 400 mg every four weeks | 52.2% (37.9, 65.7) | 27.6% (16.9, 40.3) | 11.5% (16.9, 40.3) | ||||||
Etanercept 50 mg once weekly | 61.8% (47.2, 75.6) | 36.3% (23.6, 51.7) | 16.9% (23.6, 51.7) | 60.3% (42.8, 75.1) | 35% (20.3, 51.3) | 17.3% (20.3, 51.3) | – | – | – |
Etanercept 50 mg twice weekly | 64.8% (46.7, 80.4) | 39.4% (23.2, 58.1) | 19% (23.2, 58.1) | 63.3% (40.8, 80.4) | 38% (19, 58.3) | 19.5% (19, 58.3) | – | – | – |
Etanercept 50 mg and Methotrexate 20 mg once weekly | 63% (44.4, 79.4) | 37.5% (21.5, 56.7) | 17.7% (21.5, 56.7) | 61.6% (38.7, 79.3) | 36.2% (17.5, 56.7) | 18.2% (17.5, 56.7) | – | – | – |
Golimumab 50 mg | 58.4% (43.3, 73.9) | 33% (20.6, 49.6) | 14.7% (20.6, 49.6) | 55.9% (35.3, 73.3) | 30.9% (15.3, 48.9) | 14.6% (15.3, 48.9) | – | – | – |
Golimumab 100 mg | 57.2% (42, 72.9) | 32% (19.7, 48.3) | 14.1% (19.7, 48.3) | 55% (34.6, 72.5) | 30.1% (14.8, 48) | 14.1% (14.8, 48) | – | – | – |
Infliximab 5 mg/kg | 68.4% (56.7, 79.9) | 43.2% (31.5, 57.5) | 21.8% (31.5, 57.5) | 66.6% (51.6, 79.3) | 41.4% (27.2, 56.8) | 22% (27.2, 56.8) | – | – | – |
Infliximab 5 mg/kg and methotrexate 15 mg | 76.5% (52, 92.1) | 52.9% (27.4, 77.7) | 29.6% (27.4, 77.7) | 75.3% (45, 92.2) | 51.5% (22, 77.9) | 30.2% (22, 77.9) | – | – | – |
Abatacept 125 mg | 38.4% (25.7, 51.6) | 17.2% (9.6, 27.1) | 6% (9.6, 27.1) | 45.9% (29.1, 63.8) | 22.7% (11.5, 38.4) | 9.6% (11.5, 38.4) | 26.4% (12.6, 45.1) | 11.1% (4.1, 23.9) | 3.8% (4.1, 23.9) |
Placebo | 20.7% (9.5, 37.3) | 7.1% (2.5, 16.5) | 1.9% (2.5, 16.5) | 20.9% (10.2, 36.4)† | 7.2% (2.7, 16)† | 2.2% (2.7, 16)† | 18.3% (9.6, 30.7)† | 6.8% (2.9, 13.8)† | 2% (2.9, 13.8)† |
*Key comparators include bDMARDs at doses licensed for use in PsA or PsO.
†Based on a combination of studies reporting outcomes at week 12 or 16 and week 24.
‡Based on studies reporting outcomes at week 24 only.
ACR, American College of Rheumatology; bDMARD, biological disease-modifying antirheumatic drug; PsA, psoriatic arthritis; PsO, psoriasis.